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Inhibition of platelet-derived growth factor signalling induces
autophagy in malignant glioma cells
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Malignant gliomas highly coexpress platelet-derived growth factor (PDGF) and its receptor, suggesting the presence of an autocrine
loop. Therefore, disruption of PDGF ligand/receptor complex represents a promising strategy for the treatment of malignant gliomas.
However, the mechanisms of the antitumour effect exerted by the inhibition of PDGF-mediated cell growth remain unclear. In the
present study, using anti-PDGF neutralising antibody, we investigated the effect of the inhibition of PDGF signalling on malignant
glioma U87-MG, D54, and T98G cells with high levels of PDGF-A and -B. As a control, normal fibroblast MRC5 cells expressing low
levels of PDGF-A and -B were used. Treatment with anti-PDGF neutralising antibody did not affect the expressions of PDGF-A,
PDGF-B, and Akt, but suppressed the level of phosphorylated Akt in tumour cells, indicating the inhibition of PDGF signalling. The cell
viability of all malignant glioma cells tested in this study was significantly inhibited in a time-dependent manner following the treatment
compared to that of fibroblast cells (Po0.02 to o0.05). The antitumour effect of anti-PDGF antibody was suppressed by the
activation of Akt and enhanced by the downregulation of Akt. Interestingly, the inhibition of PDGF signalling induced the
development of acidic vesicular organelles and the autophagosome membrane association of the microtubule-associated protein light
chain 3, which are characteristic of autophagy, in malignant glioma cells, while apoptotic cell death was not observed. Together these
findings imply a new concept of autophagy for PDGF autocrine inhibition in malignant gliomas.
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Malignant gliomas are the most common brain tumour, but the
cure rate and the life expectancy after the diagnosis of this tumour
is very limited in spite of recent multidisciplinary advancement in
radical surgery techniques assisted by microsurgery, imaging
device, radiation therapy, and chemotherapy (Latif et al, 1998).
Obviously, a novel treatment strategy of this tumour is required for
prolonged survival.
Malignant tumour cells are well characterised by the unfettered
reproduction through cell division of their progeny and them-
selves. One of the important factors that consist of this
phenomenon is the autocrine signalling of growth factors
(Vassbotn et al, 1993). The coexpression of platelet-derived growth
factor (PDGF) and its receptor (PDGFR) is frequently detected in a
variety of tumours including malignant glioma (Maxwell et al,
1990; Hermanson et al, 1992; Guha et al, 1995), lung cancer
(Antoniades et al, 1992), and sarcoma (Smits et al, 1992),
suggesting the existence of PDGF autocrine loop. Platelet-derived
growth factor, a potent mitogen for glial cells, vascular smooth
muscle cells, and fibroblasts, exists as disulphide-linked dimers of
four homologous polypeptide chains, PDGF-A and -B, and the
recently identified PDGF-C and PDGF-D (Ross et al, 1986; Deuel,
1987; Li et al, 2000; Bergsten et al, 2001; Gilbertson et al, 2001;
LaRochelle et al, 2001). Platelet-derived growth factor exerts
its biological activity by binding to structurally similar a-o r
b-PDGFRs. Ligand-induced receptor dimerisation leads to in-
creased tyrosine kinase activity, triggering PDGF signal transduc-
tion molecules such as phosphatidylinositol 3-kinase (PI3K)/Akt
kinase (Yu et al, 2003). The importance of PDGF signalling in
malignant gliomas is demonstrated by recent investigation that
PDGF autocrine stimulation in the brain of neonatal mice results
in the formation of gliomas (Uhrbom et al, 1998). Therefore, the
inhibition of PDGF/PDGFR complex is expected to represent a
therapeutic efficacy for malignant gliomas. To block PDGF
signalling, neutralising antibody to PDGF (Pollack et al, 1991;
Fleming et al, 1992; Vassbotn et al, 1994), dominant-negative
mutations of either PDGF or PDGFR (Vassbotn et al, 1993; Shamah
et al, 1993; Strawn et al, 1994), or the tyrosine kinase inhibitors
such as STI-571 (Kilic et al, 2000) or CT52923 (Lokker et al, 2002)
was used, and the antitumour effect in vitro and in vivo was
demonstrated. However, the mechanisms regulating the antitu-
mour effect of blocking PDGF signal transduction pathways on
malignant glioma cells remain unclear.
In the present study, using neutralising antibody to PDGF, we
investigated the effect of the inhibition of PDGF signalling on
malignant glioma cells with high levels of PDGF and fibroblast
cells with low levels of PDGF. We demonstrate that the inhibition
of PDGF signalling induces autophagy, but not apoptosis in
tumour cells, while fibroblast cells are resistant to treatment
with anti-PDGF neutralising antibody. Autophagy is a term used
to describe a process of protein degradation in response to
nutrient deprivation (Klionsky and Ohsumi, 1999; Kim and
Klionsky, 2000). Recent studies show that autophagy is induced
in tumour cells following radiation or chemotherapeutic agents
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s(Bursch et al, 1996; Paglin et al, 2001; Kanzawa et al, 2003). Our
results suggest a novel function of disruption of PDGF signalling
on tumour cells.
MATERIALS AND METHODS
Reagents
Anti-human PDGF neutralising antibody (goat) was purchased
from R&D systems (Minneapolis, MN, USA). A control antibody,
IgG from goat serum was purchased from SIGMA (St Louise, MO,
USA). Acridine orange was obtained from Polysciences (Warring-
ton, PA, USA). Activated recombinant Akt was purchased from
Upstate Biotechnology (Lake Placid, NY, USA).
Cell culture
Human malignant glioma U87-MG and T98G cells and human
normal fibroblasts MRC5 were purchased from American Tissue
Culture Collection (Rockville, MD, USA). Human malignant
glioma D54 cells were gifted by Dr F Lang (University of Texas
MD Anderson Cancer Center, Houston, TX, USA). Cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Invitro-
gen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated
fetal bovine serum, penicillin (50Uml
 1), and streptomycin
(50mgml
 1).
Cell viability assay
The effect of anti-PDGF neutralising antibody on cells was
determined by using a trypan blue dye exclusion assay as
described previously (Komata et al, 2000). Cells were seeded at
5 10
3 cellswell
 1 (0.1ml) in 96-well flat-bottomed plates (Corn-
ing, Corning, NY, USA) and incubated overnight at 371C. Then, the
cells were daily treated with anti-PDGF antibody or goat IgG at a
concentration of 1mgml
 1 for 3 days. For experiments using a
recombinant active Akt or a recombinant adenovirus carrying
dominant-negative Akt (AdDNAkt), cells were treated with anti-
PDGF antibody or goat IgG in the presence of either a recombinant
active Akt (50ng) or AdDNAkt at a multiplicity of infection (MOI)
of 20. The number of viable cells in each well was counted. Survival
fractions were calculated from the mean cell viability of treated
cells.
Western blot
Cells were lysed in NP-40 lysis buffer (0.5%. NP-40, 140mM NaCl,
10mM Tris-HCl (pH 7)), supplemented with 3mM MgCl2,2 m M
phenylmethylsulphonyl fluoride, and 5mM dithiotheitol at 41C for
30min. The cells were harvested and centrifuged at 14000g for
30min at 41C to remove cellular debris. The supernatant was
collected and protein content was measured using BCA Protein
assay reagent (Pierce, Rockford, IL, USA). Equal amounts of the
protein (40mg) from each sample were separated through 8–16%
SDS–polyacrylamide gel electrophoresis and transferred to
nitrocellulose membrane, and blocked with 5% nonfat dry milk
in TBST (1 Tris-buffered salineþ0.1% Tween 20) at room
temperature for 1h. The membrane was incubated overnight at
41C with a primary antibody diluted in 5% nonfat dry milk in
TBST. Primary antibody to actin (diluted at 1:500) was purchased
from SIGMA, and antibodies to PDGF-A and -B (diluted at 1:200)
were purchased from Santa Cruz (Santa Cruz, CA, USA). Primary
antibody to Akt (diluted at 1:1000) was purchased from Cell
Signalling Technology (Beverly, MA, USA), and antibody to
phosphorylated Akt (Thr308) (diluted at 1:1000) was purchased
from Upstate (Lake Placid, NY, USA).
The membrane was washed and then incubated for 1h at room
temperature with secondary antibody. Bound antibody was
detected using enhanced chemiluminescence’s reagent (ECL
Western Blotting System; Amersham Bioscience Corp., Piscataway,
NJ, USA).
Apoptosis detection assay
To determine if apoptotic cells are observed in treated cells, we
performed the terminal deoxynucleotidyl transferase-mediated
dUTP nick end label (TUNEL) assay using ApopTag kit (Invitro-
gen) as described previously (Komata et al, 2000). Moreover, to
determine whether treated tumour cells display apoptotic mor-
phology, tumour cells were stained with Hoechst 33258 (8mgml
 1)
as described previously (Kondo et al, 1995). Cisplatin (5mgml
 1)
was used as a positive control to induce apoptosis (Kondo et al,
1995).
Supravital cell staining with acridin orange
Cells were plated at the density of 2 10
5 cellsml
 1 for 1 day prior
to treatment and incubated overnight at 371C. Then, the cells were
treated with anti-PDGF antibody or goat IgG, respectively. This
anti-PDGF antibody or goat IgG treatment was performed every
24h for 3 days. Then acridine orange was added at a final
concentration of 1mgml
 1 for a period of 15min. The cells were
collected by trypsinisation, and green (510–530nm) and red
(4650nm) fluorescence emission from cells illuminated with blue
(488nm) excitation light was measured with FACScan using
CellQuest software as described previously (Paglin et al, 2001).
Autophagy-specific staining
Recently, the green fluorescent protein (GFP)-tagged microtubule-
associated protein light chain 3 (LC3)-expressing cells were used to
demonstrate the induction of autophagy (Kabeya et al, 2000;
Mizushima et al, 2003). Green fluorescent protein-LC3 cells
presented a diffuse distribution under control, while a punctate
pattern of GFP-LC3 was increased in number and fluorescence
intensity by autophagy. Therefore, using the GFP-LC3 expression
vector kindly supplied by Dr N Mizushima and Dr T Yoshimori,
(National Institute for Basic Biology, Japan), U87-MG cells
expressing GFP-LC3 (GFP-LC3-U87-MG cells) were established.
Briefly, transfection was performed on 100-mm plates with 10mg
plasmid DNA/plate with GenePorter (Gene Therapy System Inc.,
San Diego, CA, USA) according to the manufacturer’s instructions.
After overnight exposure, cells were washed three times with
phosphate-buffered saline and cultured in complete medium. At
48h after the medium change, cells were selected in medium
containing 400mgml
 1 of G418 (GIBCO BRL) and G-418-resistant
clones were established. To detect the localiszation of LC3, GFP-
LC3-U87-MG cells were cultured on the chamber slide dish (Fisher
Inc.). After exposure to anti-PDGF neutralising antibody or goat
IgG for 3 days, cells were fixed in 4% paraformaldehyde and
analysed by fluorescence microscopy.
Statistical analysis
The data were expressed as means7s.d. Statistical analysis was
performed by using Student’s t-test (two-tailed). The criterion for
statistical significance was taken as Po0.05.
RESULTS
Expression of PDGF in malignant glioma cells and normal
fibroblast cells
To determine the expression levels of PDGF in malignant glioma
cells and fibroblast cells, the Western blot was performed.
As shown in Figure 1, PDGF-A and -B were highly positive in
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sU87-MG, D54, and T98G cells, while the protein levels of PDGF-A
and -B were low in MRC5 cells. The intensity of PDGF-A or -B
expression in U87-MG, D54, and T98G cells was 22.1- to 32.6-fold
or 15.2- to 57.4-fold higher than in MRC5 cells, respectively. These
results indicate that U87-MG, D54, and T98G cells expressed high
levels of PDGF-A and -B, while the expression levels were very low
in MRC5 cells.
Anti-PDGF antibody reduces the level of phosphorylated
Akt in malignant glioma cells
To investigate the ability of anti-PDGF antibody to neutralise
PDGF and inhibit PDGF signalling, U87-MG cells were cultured in
the presence of anti-PDGF antibody or control antibody (goat IgG)
(1mgml
 1) for 24h. As shown in Figure 2, the Western blot
revealed that treatment with anti-PDGF antibody or control
antibody did not affect the expression of PDGF-A or -B in U87-
MG cells. Growth signal originated from PDGF/PDGFR is
transduced via PI3K/Akt pathway (Adi et al, 2001). Therefore, to
determine if treatment with anti-PDGF antibody inhibits PDGF
signalling in malignant glioma cells, the phosporylation of Akt was
examined by Western blot. As shown in Figure 2, U87-MG cells
displayed constitutive Akt phosphorylation (Thr 308) that was
inhibited to 36.9% of the no treatment by treatment with anti-
PDGF antibody, although the level of Akt protein was not
influenced. On the other hand, the effect of control antibody on
phosphorylated Akt was minimal. Similar results were observed in
other glioma cells (data not shown). These results indicate that
treatment with anti-PDGF antibody did not affect the expression
levels of PDGF-A, PDGF-B, and Akt, but reduced phosphorylated
Akt, suggesting that PDGF signalling was inhibited in malignant
glioma cells.
Anti-PDGF antibody reduces cell viability in malignant
glioma cells, but not in normal fibroblast cells
As PDGF-PDGFR autocrine signalling plays an important role in
the tumour cell survival, treatment with anti-PDGF antibody might
reduce growth of malignant glioma cells by blocking PDGF-PDGFR
autocrine loop. Therefore, we examined the effect of anti-PDGF
antibody on cell viability of malignant glioma cells with high levels
of PDGF. As shown in Figure 3A, cell proliferation of U87-MG,
D54, and T98G cells treated with anti-PDGF antibody was
significantly reduced to 41 to 74% of the cells treated with control
antibody compared to that of MRC5 cells (Po0.02 to o0.05). To
ensure that reduced viability of malignant glioma cells is due to the
inhibition of PDGF signalling, cells were further treated with anti-
PDGF antibody in the presence of a recombinant active Akt or a
recombinant adenovirus-expressing dominant-negative Akt (Ad-
DNAkt). As shown in Figure 3B, the activation of the Akt kinase
pathway by the addition of a recombinant active Akt conferred the
resistance of U87-MG cells to treatment with anti-PDGF antibody
(Po0.05). In contrast, the downregulation of Akt activity following
infection of AdDNAkt sensitised tumour cells to the treatment
(Po0.02). The presence of a recombinant active Akt or AdDNAkt
did not affect the cell viability of tumour cells treated with control
IgG. These results suggest that treatment with anti-PDGF antibody
reduced the cell growth of tumour cells via the downregulation of
Akt activity, while normal cells were insensitive to the treatment.
Anti-PDGF antibody does not induce apoptosis
To determine whether the effect of anti-PDGF antibody against
tumour cell proliferation is due to the induction of apoptosis, the
TUNEL assay and Hoechst 33258 staining were performed for U87-
MG cells treated with anti-PDGF or control antibody. As shown in
Figure 4, a significant number of TUNEL-positive (c) or DNA-
condensed or -fragmented cells (f) were detected following the
treatment with cisplatin (5mgml
 1) for 2 days. However, there
were almost no TUNEL-positive or morphologically apoptotic cells
in U87-MG cells treated with anti-PDGF (Figure 4B or E) or control
antibody (Figure 4A or D). These results indicate that the
antitumour effect of the inhibition of PDGF signalling was not
due to the induction of apoptosis.
Anti-PDGF antibody develops acidic vesicular organelles
(AVOs)
Recently, we and other investigators have demonstrated that
radiation or some chemotherapeutic agents induce autophagy, but
U87-MG
PDGF-A
PDGF-B
Actin
D54 T98G MRC5
Figure 1 Expression of PDGF in malignant glioma cells and normal
fibroblast cells. Aliquots of 40mg of protein extract from U87-MG, D54,
T98G, or MRC5 cells were used for immunoblotting assay using anti-
PDGF-A or -PDGF-B antibody. The anti-b-actin monoclonal antibody was
used for protein-loading equivalence. Data shown are representative of
three independent experiments.
No treatment
Anti-PDGF Ab
Control Ab (goat IgG)
PDGF-A
PDGF-B
Akt
Phospho-Akt (Thr 308)
Actin
Figure 2 Effect of neutralising anti-PDGF antibody on expression of
PDGF-A, PDGF-B, Akt, or phosphorylated Akt in malignant glioma cells.
Aliquots of 40mg of protein extract from U87-MG cells treated with anti-
PDGF or control antibody (1mgml
 1) for 24h were used for
immunoblotting assay using anti-PDGF-A, -PDGF-B, -Akt, or -phosphory-
lated Akt (Thr 308) antibody. The anti-b-actin monoclonal antibody was
used for protein-loading equivalence. Data shown are representative of
three independent experiments.
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snot apoptosis with increased autophagosomes in tumour cells
(Bursch et al, 1996; Paglin et al, 2001; Kanzawa et al, 2003; Yao
et al, 2003). Autophagy is characterised by the development of
AVOs. To identify the development of AVOs in malignant glioma
cells treated with anti-PDGF antibody, we used the lysosomotropic
fluorescent dye acridine orange, a weak base that moves
freely across biological membranes when uncharged. In acridine
orange-stained cells, the cytoplasm and nucleolus fluoresce bright
green and dim red, whereas acidic compartments fluoresce bright
red (Paglin et al, 2001). As shown in Figure 5A, anti-PDGF
antibody increased the strength of the bright red fluorescence
(y-axis) in U87-MG cells from 4.87 to 14.22%, indicating
the development of AVO. On the other hand, significant
development of AVO was not detected in U87-MG cells treated
with control antibody (4.35%). These results indicate that the
inhibition of PDGF signalling induces autophagic change in
malignant glioma cells.
Anti-PDGF antibody induces autophagosome membrane
association of LC3
Although the induction of autophagy is usually associated with
the increase in the number of acidic compartments (autolyso-
somes), the induction of AVO does mean the activation of the
lysosomal system. Therefore, as a specific assay for autophagy,
GFP-LC3-expressing vectors were used in several cases to
demonstrate the induction of autophagy (Kabeya et al, 2000;
Munafo and Colombo, 2001; Mizushima et al, 2003). Therefore,
GFP-LC3-expressing U87-MG cells were treated with anti-PDGF
or control antibody in order to observe the formation of
autophagosome following the treatment. As shown in Figure 5B,
GFP-LC3 presented diffuse distribution in tumour cells treated
with control antibody. In contrast, after treatment with anti-
PDGF antibody for 3 days, a punctate pattern of GFP-LC3
was detected in some cells. The percentage of cells showing
this autophagic pattern of GFP-LC3 expression following
the treatment with anti-PDGF antibody increased from 9.9%
(no treatment) or 10.8% (control Ab) to 21.7% (Po0.001;
Figure 5C). These results indicate that the inhibition of PDGF
signalling formed autophagosome and promoted autophagy in
U87-MG cells.
DISCUSSION
In the present study, we demonstrate that the expressions of
PDGF-A and -B were significantly higher in malignant glioma
cells than non-tumoral fibroblast cells. It is consistent with the
previous findings that malignant gliomas (anaplastic astrocytomas
and the most malignant type, glioblastoma multiforme) over-
express the ligands PDGF-A and -B compared to low-grade
gliomas or normal tissues (Maxwell et al, 1990; Hermanson et al,
1992; Guha et al, 1995). Moreover, the retrovirus-mediated
expression of PDGF-B in the brain of neonatal mice results in
the formation of astrocytomas (Uhrbom et al, 1998). These
observations support the importance of PDGF signalling in
malignant gliomas. Accordingly, it is reasonable to treat malignant
gliomas with the inhibition of PDGF signalling. To date, several
approaches for disruption of PDGF/PDGFR pathway are intro-
duced. Using a neutralising anti-PDGF antibody or dominant-
negative mutation of PDGF, PDGF signalling is inhibited, resulting
in diminished DNA synthesis, the inhibition of tumour colony
growth, and reversion of the transformed morphology of
the tumour cells (Pollack et al, 1991; Fleming et al, 1992; Shamah
et al, 1993; Vassbotn et al, 1993, 1994). In addition, treatment
with the truncated PDGFR or the PDGFR tyrosine kinase inhibitors
such as STI-1571 or CT52923 inhibited PDGFR signaling, and
the in vitro and in vivo growth of malignant gliomas (Strawn et al,
1994; Kilic et al, 2000; Lokker et al, 2002). However, very little
is known about what plays a central role in the antitumour
effect observed following the inhibition of PDGF/PDGFR signalling
pathway. We here demonstrate that the inhibition of PDGF
signalling by a neutralising anti-PDGF antibody suppressed
the proliferation of malignant glioma cells with high levels of
PDGF through the inhibition of Akt activity, resulting in the
induction of autophagy, but not apoptosis. In contrast, normal
fibroblast cells expressing low levels of PDGF were resistant to
the treatment with anti-PDGF antibody. To our knowledge, the
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Figure 3 Effect of neutralising anti-PDGF antibody on cell viability of
malignant glioma cells. (A) Inhibition of cell viability in malignant glioma cells
following the treatment with anti-PDGF antibody. Tumour cells (U87-MG,
D54, and T98G) and fibroblast MRC5 cells were seeded at 5 10
3
cellswell
 1 (0.1ml) in 96-well flat-bottomed plates and incubated over-
night at 371C. After exposure to anti-PDGF or control antibody
(1mgml
 1) for 1–3 days, the cells were trypsinised and the number of
viable cells was counted. The viability of the cells treated with control
antibody was regarded as 100%. Results shown are the means7s.d. of
three independent experiments. *Po0.05, **Po0.02. (B) Effect of
extrinsic activation or inactivation of Akt on cell viability. U87-MG cells
were treated with anti-PDGF antibody or control antibody in the presence
of recombinant active Akt (50ng) or adenovirus-mediated dominant-
negative Akt (20MOI) for 3 days. Results shown are the means7s.d. of
three independent experiments. *Po0.02, **Po0.05.
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spresent study is the first report demonstrating that autophagy
is induced in malignant glioma cells by disruption of PDGF
signalling.
Autophagy is characterised by the accumulation of autophagic
vacuoles, and is well described as the degradation of normal
proteins in response to nutrient deprivation or other types of
stresses (Klionsky and Ohsumi, 1999; Kim and Klionsky, 2000).
In the process of autophagy, cytoplasmic materials are sequestered
by a membrane vacuole called autophagosome. Autophagosome
then fuses with lysosome, where the materials inside are
degraded by lysosomal hydrolases. Using this process, autophagy
recycles molecules for biosynthetic reactions. In the present
study, the inhibition of PDGF signalling induced the development
of AVOs and increased punctate patterns of GFP-LC3 character-
istic of autophagy. LC3 is a mammalian homologue of Apg8p/
Aut7p essential for autophagy in yeast (Kabeya et al, 2000)
and is recruited to the autophagosome membrane in the Apg5-
dependent manner (Mizushima et al, 2001). Therefore, autophago-
some membrane association of LC3 is a specific marker
for autophagy (Kabeya et al, 2000; Munafo and Colombo, 2001;
Mizushima et al, 2003). Recent investigations suggest that
autophagy plays a defensive role in cancer therapy (Bursch
et al, 1996; Paglin et al, 2001; Ogier-Denis and Codogno,
2003). Therefore, if it is the case, the inhibition of autophagy
may enhance the antitumour effect of the inhibition of PDGF
signalling.
PDGF autocrine signalling characterised by the coexpression of
PDGF and PDGFR contributes to the development of a variety of
tumours including malignant gliomas as a major signal pathway
(Maxwell et al, 1990; Antoniades et al, 1992; Hermanson et al,
Figure 4 Apoptosis detection assays for malignant glioma cells treated with anti-PDGF antibody. After the treatment with anti-PDGF (B) or control
antibody (A)( 1 mgml
 1) for 72h, U87-MG cells were fixed, labelled with Br-dUTP, and stained with anti-Br-dUTP antibody for TUNEL analysis. As a
positive control for apoptosis, U87-MG cells were treated with cisplatin (5mgml
 1) for 2 days (C). To evaluate apoptotic morphological changes in U87-MG
cells treated with control (D), anti-PDGF antibody (E), or cisplatin (F), the cells were fixed and stained with Hoechst 33258 (8mgml
 1). Arrows indicate
representative apoptotic cells. Data shown are representative of three independent experiments. Bar, 10mm.
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Figure 5 Induction of autophagy in malignant glioma cells following the
treatment with anti-PDGF antibody. (A) Development of AVOs in U87-
MG cells treated with anti-PDGF antibody. Detection of green and red
fluorescence in acridine orange-stained cells was performed using FACS
analysis. Tumour cells were treated with anti-PDGF or control antibody
(1mgml
 1) for 3 days. FL1-H indicates green color intensity, while FL3-H
shows red color intensity. Data shown are representative of three
independent experiments. (B) Involvement of LC3 autophagosome
membrane association in the inhibition of PDGF signalling. Green
fluorescent protein-LC3-U87-MG cells were treated with anti-PDGF or
control antibody (1mgml
 1) for 3 days and examined by fluorescence
microscopy. Arrows indicate representative autophagic cells. Data shown
are representative of three independent experiments. Bar, 10mm. (C) The
percentage of cells showing punctate pattern of LC3 after treatment with
anti-PDGF antibody. After the treatment with anti-PDGF or control
antibody (1mgml
 1) for 3 days, the percentage of autophagy was
quantified by counting the number of the cells showing the punctate
pattern of LC3-GFP in 50 GFP-positive cells. Results shown are the
means7s.d. of three independent experiments. *Po0.001.
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s1992; Smits et al, 1992; Vassbotn et al, 1993; Guha et al, 1995).
Secreted PDGF binds to extracellular domain of cell surface
PDGFR, resulting in receptor dimerisation. Ligand binding is
required for the stability of the receptor dimers and their
activation. Platelet-derived growth factor receptor is classified
as the receptor protein tyrosine kinases that are so named since
they are activated when specific tyrosine residues on the
intracellular domain of the receptor are phosphorylated. After
dimerisation, phosphorylated tyrosine residues interact with Src
homology 2 domains of intracellular signalling molecules includ-
ing PI3K/Akt (Heidaran et al, 1993; Kazlauskas et al, 1993; DeMali
et al, 1997; Rosenkranz and Kazlauskas, 1999). In the present
study, anti-PDGF antibody reduced phosphorylation of Akt,
indicating that PDGF signalling leading to PI3K/Akt activation
is suppressed. The activation of Akt using activated recombinant
Akt suppressed the antitumour effect of anti-PDGF antibody,
while the inhibition of Akt with AdDNAkt augmented anti-PDGF
antibody-induced cytotoxicity. These results suggest that the
inhibition of Akt signalling might play an important role in
the induction of autophagy in malignant glioma cells. Activated
signalling molecules further transduce signal transduction
pathways by activating downstream signalling molecules such as
mitogen-activated protein kinase family members (Yu et al,
1994; Choudhury et al, 1997; Maudsley et al, 2000; Lokker
et al, 2002). These signals enter the nucleus and stimulate
the expression of a set of immediate-early response genes
mediating PDGF-induced cellular processes such as cell cycle,
migration, and transformation. On the other hand, there is
accumulating evidence that autophagy is a multistep process and
a variety of signalling kinases have been implicated in the
upregulation or downregulation of autophagy (Bursch et al,
2000; Klionsky and Emr, 2000; Ogier-Denis and Codogno, 2003).
In particular, PI3K is an important factor in autophagic process
(Klionsky and Ohsumi, 1999; Kabeya et al, 2000; Kim and
Klionsky, 2000; Mizushima et al, 2001; Munafo and Colombo,
2001; Paglin et al, 2001). Three classes of PI3K have been defined
so far. Class I PI3K is involved in the inhibitory effect on
autophagy, while the class III PI3K is involved in the sequestration
of cytoplasmic material in autophagy (Petiot et al, 2000). There-
fore, autophagy induced by the inhibition of PDGF signalling may
be due to the inhibitory effect on class I PI3K and/or the
stimulatory effect on class III PI3K. Further study is necessary to
investigate the molecular mechanisms regulating the induction of
autophagy in malignant glioma cells treated with anti-PDGF
antibody.
In conclusion, the inhibition of PDGF signalling by a neutralis-
ing anti-PDGF antibody suppressed the proliferation of malignant
glioma cells through the induction of autophagy, but not
apoptosis. In contrast, normal fibroblast cells with low levels of
PDGF were significantly resistant to the anti-PDGF antibody
therapy. These findings provide strong evidence that the inhibition
of PDGF signalling exhibits antitumour effect only on tumour cells
and autophagy plays a key role in its efficacy.
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